PDAC - Pancreatic Ductal Adenocarcinoma Clinical Trials

41 clinical trials for PDAC - Pancreatic Ductal Adenocarcinoma across international registries, including 23 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma — RECRUITING · PHASE3
• Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 ) — RECRUITING · PHASE3
• Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) — RECRUITING · PHASE3
• PDAC-PATHWAYS: A Digital Informational and Supportive Care App for Patients Initiating Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma — RECRUITING · NA
• Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma — RECRUITING · PHASE3
• Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in PDAC Patients — RECRUITING · PHASE2
• Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma (VAPOR2) — RECRUITING
• Biophotonic Nanoparticle-enabled Laser Blood Test for Early Detection of Pancreatic Cancer — RECRUITING · NA
• A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations — RECRUITING · PHASE1
• AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors — RECRUITING · PHASE1
• BBO-11818 in Adult Subjects With KRAS Mutant Cancer — RECRUITING · PHASE1
• Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals — RECRUITING · PHASE1
• Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma — RECRUITING
• Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients — RECRUITING · PHASE1
• Functional, Personalised and Integrated Profiling of Biopsied Pancreatic Tumours (CancerProfile by FNB) — RECRUITING · NA
• A Prospective Registry for Patients at High-Risk for Pancreatic Cancer — RECRUITING
• Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer — RECRUITING · PHASE1
• Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA) — RECRUITING · PHASE4
• Monitoring and Managing Glucose Levels in People With Pancreatic Cancer — RECRUITING · NA
• Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer — RECRUITING
• Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer — RECRUITING · PHASE1
• Prospective Registry of Young-Adult Patients Diagnosed With Pancreatic Cancer — RECRUITING
• Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma — OTHER
• IKS04 Regimen in Advanced Solid Tumors That Express CA242 — NOT_YET_RECRUITING · PHASE1
• Intermediate-size IND for Treatment of Patients With Advanced Cancer Using T Cells Engineered to Express TCR Targeting Mutant KRAS — OTHER
• Exploratory Clinical Evaluation of Personalized Functional Profiling in GI Tumors: Predicting Drug Response in CRC and PDAC — NOT_YET_RECRUITING
• Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) — ACTIVE_NOT_RECRUITING · PHASE3
• Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma — COMPLETED · PHASE2
• The Canopy Cancer Collective Clinical Registry Protocol — NOT_YET_RECRUITING
• Forecasting Occult liveR Metastasis Using an Exosomal Signature for Intelligent Guided Hepatic Targeting — COMPLETED
• Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC) — ACTIVE_NOT_RECRUITING · PHASE1
• A Phase III, Randomized, Clinical Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients With Recurrent or Metastatic Pancreatic Cancer (WGOG-PAN 006/ICSBR-2) — NOT_YET_RECRUITING · PHASE3
• Magnetic Resonance Imaging (MRI) to Predict Outcomes of Pancreatic Ductal Adenocarcinoma (PDAC) — SUSPENDED · NA
• Early Detection of PDAC in Patients With Chronic Pancreatitis — COMPLETED
• PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment — NOT_YET_RECRUITING · PHASE2
• Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC — WITHDRAWN · PHASE1
• Clinical Validation of Immunovia Next-Generation Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer — COMPLETED
• Circulating Tumor DNA as Surgical Biomarker in Patients With PancrEatic Adenocarcinoma for Statement of Resectability — OTHER · NA
• Defining a Vascular Phenotype of Pancreatic Ductal Adenocarcinoma With CT Perfusion Using Quantitative Radiomics — OTHER · NA
• Nab-Paclitaxel and Gemcitabine Plus Camrelizumab and Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma — OTHER

Refine this search